Curated News
By: NewsRamp Editorial Staff
November 04, 2026
Tonix Pharmaceuticals to Present at Guggenheim Healthcare Conference
TLDR
- Tonix Pharmaceuticals will present at Guggenheim's Healthcare Innovation Conference, giving investors early access to its CNS pipeline and flagship fibromyalgia drug TONMYA.
- Tonix CEO Seth Lederman will present from 4 to 4:25 p.m. ET on Nov. 10, 2026, with a live webcast and replay available on the company's website.
- Tonix's TONMYA offers the first new fibromyalgia treatment in over 15 years, addressing high unmet medical needs in CNS and immunology.
- Tonix is testing TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, expanding its potential beyond fibromyalgia.
Impact - Why it Matters
This news matters because it gives investors and industry watchers a direct opportunity to hear from Tonix’s leadership about the company’s commercial-stage products and pipeline. With TONMYA recently approved as the first new fibromyalgia treatment in over 15 years, and with additional Phase 2 programs in depression and acute stress disorder, Tonix is at a pivotal point. The presentation could provide updates on commercialization strategy, clinical progress, and the potential of its immunology assets, which may influence investment decisions and the company’s visibility in the competitive biotech landscape.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that management will present and host one-on-one meetings at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET. A live webcast and replay will be available under the News & Events tab in the Investors section of the company’s website.
Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine products Zembrace® SymTouch® and Tosymra®. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, and its CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome. Additionally, Tonix is advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for prevention of kidney transplant rejection. For full details, view the full press release at https://ibn.fm/f7udM.
The announcement highlights Tonix’s commitment to engaging with the investment community and showcasing its diverse pipeline. InvestorWire, a specialized communications platform, powered by IBN, is the distributor of this news. The latest updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals to Present at Guggenheim Healthcare Conference
